Macrophage depletion increases target specificity of bone-targeted nanoparticles

Despite efforts to achieve tissue selectivity, the majority of systemically administered drug delivery systems (DDSs) are cleared by the mononuclear phagocyte system (MPS) before reaching target tissues regardless of disease or injury pathology. Previously, we showed that while tartrate-resistant acid phosphatase (TRAP) binding peptide (TBP)-targeted polymeric nanoparticles (TBP-NP) delivering a bone regenerative Wnt agonist improved NP fracture accumulation and expedited healing compared with controls, there was also significant MPS accumulation. Here we show that TBP-NPs are taken up by liver, spleen, lung, and bone marrow macrophages (M phi), with 76 +/- 4%, 49 +/- 11%, 27 +/- 9%, and 92 +/- 5% of tissue-specific M phi positive for NP, respectively. Clodronate liposomes (CLO) significantly depleted liver and spleen M phi, resulting in 1.8-fold and 3-fold lower liver and spleen and 1.3-fold and 1.6-fold greater fracture and naive femur accumulation of TBP-NP. Interestingly, depletion and saturation of MPS using 10-fold greater TBP-NP doses also resulted in significantly higher TBP-NP accumulation at lungs and kidneys, potentially through compensatory clearance mechanisms. The higher NP dose resulted in greater TBP-NP accumulation at naive bone tissue; however, other MPS tissues (i.e., heart and lungs) exhibited greater TBP-NP accumulation, suggesting uptake by other cell types. Most importantly, neither M phi depletion nor saturation strategies improved fracture site selectivity of TBP-NPs, possibly due to a reduction of M phi-derived osteoclasts, which deposit the TRAP epitope. Altogether, these data support that MPS-mediated clearance is a key obstacle in robust and selective fracture accumulation for systemically administered bone-targeted DDS and motivates the development of more sophisticated approaches to further improve fracture selectivity of DDS.

Automated summary

The study demonstrates that bone-targeted drug delivery nanoparticles are taken up by macrophages in the liver, spleen, lungs, and bone marrow, with mononuclear phagocyte system (MPS)-mediated clearance being a key obstacle to their accumulation at fracture sites. Further development of sophisticated approaches is needed to improve the selectivity of the nanoparticles.